Centric Wealth Management’s Starling Oncology STLN Stock Holding History

Centric Wealth Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$100K	–	205
2021 Q1	$100K	Hold	10,000	–	–	0.03%	197
2020 Q4	$108K	Buy	+10,000	New	+$103K	0.03%	188

Other funds holding STLN

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Millennium Management

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Centric Wealth Management's STLN Position: Q2 2021 in Review

Centric Wealth Management sold out of Starling Oncology (STLN) in Q2 2021, closing a stake of 10,000 shares — an estimated $100K sold.

Centric Wealth Management first reported a position in STLN in Q4 2020 and held it in 2 quarters. The position peaked at $108K in Q4 2020. 53 funds tracked by Wall St. Rank hold STLN as of Q2 2021.

Centric Wealth Management reported no remaining Starling Oncology position as of Q2 2021 after selling out during the quarter.
Centric Wealth Management sold 10,000 Starling Oncology shares in Q2 2021, an estimated $100K.
Centric Wealth Management first reported a position in Starling Oncology in Q4 2020 and held it in 2 quarters.
Centric Wealth Management's Starling Oncology position peaked at $108K in Q4 2020.
53 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2021.

Based on Centric Wealth Management's 13F filing for Q2 2021, filed 21 Jul 2021.